The Renin-Angiotensin-Aldosterone System and Heart Failure

Cardiology Clinics

Volumn 32, Issue 1, 2014, Pages 21-32

  Sayer, Gabriel ^a,b   Bhat, Geetha ^a,b  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Aldosterone; Angiotensin II; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Heart failure; Neurohormonal; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPOTENSION; ISCHEMIC CARDIOMYOPATHY; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSIN-RECEPTOR BLOCKERS; HEART FAILURE; NEUROHORMONAL; RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84888212540     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.09.002     Document Type: Review

References (69)

1. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456.
2. Fauchier L., Pierre B., de Labriolle A., et al. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2007, 9:1136-1139.
3. Pfeffer M.A., Pfeffer J.M., Steinberg C., et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985, 72(2):406-412.
4. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure. JAm Coll Cardiol 2013, 10.1016/j.jacc.2013.05.019.
5. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012, 33:1787-1847.
6. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. JCard Fail 2010, 16:e1-e194.
7. Bock H.A., Hermle M., Brunner F.P., et al. Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 1992, 41:275-280.
8. Urata H., Healy B., Stewart R.W., et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990, 66:883-890.
9. Seikaly M.G., Arant B.S., Seney F.D. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. JClin Invest 1990, 86:1352-1357.
10. van Kats J.P., Danser A.H., van Meegen J.R., et al. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998, 98:73-81.
11. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993, 153:937-942.
12. Vallotton M.B., Gerber-Wicht C., Dolci W., et al. Interaction of vasopressin and angiotensin II in stimulation of prostacyclin synthesis in vascular smooth muscle cells. Am J Physiol 1989, 257:E617-E624.
13. Baker K.M., Aceto J.F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990, 259:H610-H618.
14. Harrap S.B., Dominiczak A.F., Fraser R., et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996, 93:1148-1154.
15. Peng J., Gurantz D., Tran V., et al. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002, 91:1119-1126.
16. Weber K.T. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082.
17. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
18. Yoshida M., Ma J., Tomita T., et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005, 11:12-16.
19. Brilla C.G., Zhou G., Matsubara L., et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. JMol Cell Cardiol 1994, 26:809-820.
20. Harada E., Yoshimura M., Yasue H., et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001, 104:137-139.
21. Hornig B., Kohler C., Drexler H. Role of bradykinin inmediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997, 95:1115-1118.
22. Levine T.B., Olivari M.T., Garberg V., et al. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984, 69:548-553.
23. Uretsky B.F., Shaver J.A., Liang C.S., et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J 1988, 116:480-488.
24. Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985, 57:84-95.
25. Sharpe N., Smith H., Murphy J., et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991, 337:872-876.
26. St John Sutton M., Pfeffer M.A., Plappert T., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89:68-75.
27. Konstam M.A., Rousseau M.F., Kronenberg M.W., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992, 86:431-438.
28. Konstam M.A., Kronenberg M.W., Rousseau M.F., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
29. Enalapril for congestive heart failure. NEngl J Med 1987, 317:1349-1351.
30. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEngl J Med 1991, 325:293-302.
31. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. NEngl J Med 1992, 327:685-691.
32. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. NEngl J Med 1992, 327:669-677.
33. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
34. Kober L., Torp-Pedersen C., Carlsen J.E., et al. Aclinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 1995, 333:1670-1676.
35. Cohn J.N., Johnson G., Ziesche S., et al. Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med 1991, 325:303-310.
36. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312-2318.
37. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEngl J Med 2000, 342:145-153.
38. Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
39. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. NEngl J Med 2004, 351:2058-2068.
40. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368:581-588.
41. Havranek E.P., Thomas I., Smith W.B., et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. JAm Coll Cardiol 1999, 33:1174-1181.
42. Lang R.M., Elkayam U., Yellen L.G., et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. JAm Coll Cardiol 1997, 30:983-991.
43. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
44. Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002, 360:752-760.
45. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. NEngl J Med 2003, 349:1893-1906.
46. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
47. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848.
48. Cohn J.N., Tognoni G., Valsartan Heart Failure TrialInvestigators Arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001, 345:1667-1675.
49. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
50. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
51. Kim S., Yoshiyama M., Izumi Y., et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001, 103:148-154.
52. Baruch L., Anand I., Cohen I.S., et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999, 99:2658-2664.
53. Hamroff G., Katz S.D., Mancini D., et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999, 99:990-992.
54. Lakhdar R., Al-Mallah M.H., Lanfear D.E. Safety andtolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. JCard Fail 2008, 14:181-188.
55. Fraccarollo D., Galuppo P., Hildemann S., et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. JAm Coll Cardiol 2003, 42:1666-1673.
56. Suzuki G., Morita H., Mishima T., et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967-2972.
57. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559-2565.
58. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000, 102:2700-2706.
59. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEngl J Med 1999, 341:709-717.
60. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348:1309-1321.
61. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
62. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. NEngl J Med 2004, 351:543-551.
63. McMurray J.J., Pitt B., Latini R., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17-24.
64. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. NEngl J Med 2012, 367:2204-2213.
65. Solomon S.D., Shin S.H., Shah A., et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. Eur Heart J 2011, 32:1227-1234.
66. Gheorghiade M., Bohm M., Greene S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309:1125-1135.
67. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
68. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
69. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.